NOVO Nordisk said the heart-protective benefits of its Wegovy (semaglutide) obesity drug are due to more than weight loss alone, according to new data, Reuters has reported.
Full results from the study, presented at the American Heart Association annual scientific meeting in Philadelphia in front of a standing-room-only crowd and published in the New England Journal of Medicine, suggest the drug has other beneficial effects beyond the known health benefits from losing weight.
The heart risk difference between patients who received Wegovy and those on placebo "began to appear almost immediately after starting treatment," researchers said.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Nov 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Nov 23
